Previous 10 | Next 10 |
home / stock / phguf / phguf news
The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21, 2023: Pharming Group N.V. (“Pharming” or “the Comp...
Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of November: Stifel 2023 Healthcare Confer...
2023-10-27 08:35:10 ET Pharming Group N.V. (PHAR) Q3 2023 Earnings Conference Call October 26, 2023 07:30 AM ET Company Participants Sijmen de Vries - Chief Executive Officer Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen ...
2023-10-26 22:33:09 ET Pharming Group N.V. (PHGUF) Q3 2023 Earnings Conference Call October 26, 2023 7:30 AM ET Company Participants Sijmen de Vries - Chief Executive Officer Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen ...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
Pharming Group reports third quarter 2023 financial results Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and the U.S. commercial launch of Joenja® Nine month year to date 2023 revenues inc...
Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023. Ph...
Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders ap...
DocuSign Inc. (DOCU) is expected to report $0.11 for Q2 2024 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Concrete Pumping Holdings Inc. (BBCP) is expected to report $0.16 for Q3 2023 ...
Pharming Group N.V. (PHGUF) is expected to report for quarter end 2023-06-30
News, Short Squeeze, Breakout and More Instantly...
Pharming Group Nv Ord Company Name:
PHGUF Stock Symbol:
OTCMKTS Market:
First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST® RUCONEST® revenues increased by 8% to US$46.0 million, compared to the first quarte...
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming” or “...
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHAR...